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Abstract
Purpose We aimed to quantify the relative risk of progression from mild cognitive impairment (MCI) to dementia in people 
with and without diabetes, and with and without the MetS (MetS); and to identify potential modifiers of the risk of progres-
sion from MCI to dementia in people with diabetes or MetS.
Methods We searched Medline, Embase, PsycINFO, PsycArticles and Web of Science from inception through to 20th 
March 2018. Where possible, the results from three or more studies were pooled in a meta-analysis, while other findings 
have been described narratively.
Results We included 15 articles reporting 12 studies (6865 participants). The overall unadjusted pooled odds ratio for 
the progression of MCI to dementia in people with diabetes/MetS was 1.67 (95% CI 1.27–2.19); the pooled odds ratio for 
progression in diabetes + MCI was 1.53 (95% CI 1.20–1.97) and in people with MetS + MCI was 2.95 (95% CI 1.23–7.05). 
There was moderate heterogeneity in the included studies (I2 < 60%). In diabetes, a longer duration of diabetes and the pres-
ence of retinopathy were associated with an increased risk of progression, while the use of statins and oral hypoglycaemic 
agents reduced the risk. Having multiple cardiovascular risk factors was a significant risk factor for progression from MCI 
to dementia in people with MetS.
Conclusions Diabetes and MetS were both associated with an increased incidence of dementia when co-existing with MCI. 
Intensive cardiovascular risk reduction and lifestyle changes for patients presenting with MCI and diabetes, prediabetes or 
MetS may be important in reducing incidence of dementia in this high risk population.
Keywords MCI · Dementia · T2D · Systematic review · Meta-analysis
Introduction
Demographic and lifestyle changes have seen dementia 
and diabetes become growing challenges to healthcare sys-
tems across the world. Dementia affects 50 million people 
worldwide, with the most common types of dementia being 
Alzheimer’s disease (AD) and vascular dementia (VaD) [1]. 
Less severe forms of cognitive dysfunction that precede the 
development of dementia affect many more people, with 
mild cognitive impairment (MCI) affecting 6% of the popu-
lation [2], and 1 in 5 people aged 65 or older [3]. MCI is a 
condition that lies between age-appropriate cognition and 
dementia. It is defined as objective cognitive impairment 
relative to the person’s age, with concern about the cognitive 
symptoms, in a person with essentially normal functional 
activities who does not have dementia [4]. MCI is a het-
erogeneous condition with a particular subtype, amnestic 
MCI, linked to the development of Alzheimer’s disease [5, 
6]. People with MCI are high risk for developing dementia 
with around 46% developing dementia within 3 years, com-
pared to 3% of an age-matched population [7].
Diabetes has been identified as a key risk factor for 
dementia and MCI [4, 8, 9], so the growing prevalence of 
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glycaemic disorders [10] has the potential to further increase 
the burden of MCI and dementia on healthcare systems. 
Understanding the links between cognitive impairment and 
diabetes, and the risk factors that might predict progression 
to dementia in people with diabetes is important in trying to 
mitigate such risks [11].
MCI and risks of progression to dementia
The development of dementia is complex multifactorial 
degenerative process that evolves over time. People with 
MCI represent an important high risk group for developing 
dementia, especially in the context of attempts at disease 
modification and trying to influence the trajectory of this 
process [12]. The factors that play a part in this progression 
are a combination of discrete (non-modifiable) elements 
that reduce cognitive reserve (e.g. cerebrovascular events 
and lower educational status) and exposures that accelerate 
neurodegenerative processes and affect the trajectory of cog-
nitive decline (e.g. microvascular disease and Alzheimer’s 
disease) [8]. This review focuses on the subset of potentially 
modifiable risks in people with MCI and diabetes/metabolic 
syndrome to identify potential targets to reduce conversion 
from MCI to dementia in this higher risk population.
Disturbances of glycaemic control and metabolic 
syndrome as risk factors for disorders of cognition
Type 2 diabetes (T2D) has been associated with a modest 
increased risk in cognitive dysfunction across all cognitive 
domains [13]. This effect appears to be consistent across 
all age groups and mimics an accelerated ageing of brain 
function [14]. However there is also an increased risk of 
more severe impairment of cognition and developing demen-
tia in older age groups that would appear to be a different 
phenomenon. The onset of dementia in people with T2D 
is on average 2.5 years earlier than in comparable popula-
tions without diabetes [11]. The relative risks of developing 
any cause dementia and VaD in people with T2D have been 
estimated to be 1.51 (95% CI 1.31–1.74) and 2.48 (95% CI 
2.08–2.96), respectively [15]. Vascular damage and dysfunc-
tions in glucose, insulin and amyloid metabolism in T2D 
have been proposed as mechanisms underlying this increased 
risk [16]. It is likely that T2D reduces cognitive reserve and 
increases brain susceptibility to significant insults from cer-
ebrovascular events or dysfunctional amyloid processing.
A metabolic state that lies between normal glucose 
homeostasis and T2D has been defined as prediabetes [17]. 
Risk factors associated with prediabetes have been associ-
ated with increased dementia risk in prospective and epide-
miological studies [18–21]. The prevalence of prediabetes 
in adult populations is rapidly rising, estimated as 35% in 
the UK and USA and up to 50% in China [22]. Associated 
with this is the metabolic syndrome (MetS)—a collection of 
cardiovascular risk factors that has been associated with an 
increased risk of developing cardiovascular disease, diabe-
tes, mortality, and other important adverse health outcomes 
[23]. There are a number of different definitions for the 
MetS based on five cardiovascular risk factors that include 
abdominal obesity, hypertriglyceridemia, low high-density 
lipoprotein (HDL) levels, hypertension, and hyperglycaemia 
[24]. In research studies, a commonly used consensus defini-
tion is the presence of at least three of those risk factors [25]. 
Diabetes, prediabetes and MetS overlap significantly [25].
Understanding the link between metabolic 
disturbances and progression of MCI to dementia
A systematic review of modifiable risk factors for the pro-
gression of MCI to dementia identified diabetes and pre-
diabetes as important predictors [4]. We assimilate below 
current evidence that may explain this relationship, or iden-
tify modifiers of this increased dementia risk in people with 
T2D, prediabetes and MetS.
Cardiovascular and metabolic risks
Hypertension Raised blood pressure has been identified as 
a risk factor for developing dementia in older people with 
T2D in cohort studies [26, 27]. However, findings from a 
systematic review did not find that hypertension predicted 
progression from any-type MCI to dementia in the general 
population [4]. A Dutch cohort study found an association 
between slight cognitive decline and higher blood pressure 
in the prediabetes stage [28].
Adiposity Midlife total body adiposity and central adi-
posity have been associated with increased risks of demen-
tia and are also common in people with T2D, prediabe-
tes and MetS. Results from a prospective cohort study of 
10,276 people in the USA found a hazard ratio for devel-
oping dementia of 1.74 in people with a body mass index 
(BMI) ≥ 30 and a hazard ratio of 1.35 (95% CI 1.14–1.60) 
in people with a BMI of 25–29.9 [21]. A systematic review 
found an association between high BMI and increased risk 
of dementia in five out of nine studies [19].
Cholesterol Increased blood cholesterol levels in midlife 
(but not later life) are associated with increased dementia 
risk in the general population [19, 29]. In people living with 
T2D, results have been mixed with dyslipidaemia being 
associated with both increased and decreased risks of cog-
nitive impairment [27, 30]. Cholesterol levels in later life do 
not appear to increase the risk of progression from any-type 
MCI to all-cause dementia [4].
Glycaemic control There are four main aspects of glycae-
mic control that have been reported to be associated with 
dementia risk in people living with diabetes—duration of 
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diabetes, blood glucose control (e.g. HbA1c and fasting 
plasma glucose), use of medication and episodes of hypo-
glycaemia. An increase in dementia risk of 40–60% in peo-
ple who have been living with diabetes for 5 years or more 
relative to those more recently diagnosed is reported [30, 
31]. Higher mean blood glucose readings may be associated 
with an increased risk of dementia [32], but not in older 
patients over 85 [33]. The use of oral hypoglycaemic agents 
(and statins), but not insulin, has been linked to a lower risk 
of developing dementia [31]. Hypoglycaemia appears to 
have a bi-directional association with cognitive impairment 
[34–36].
Other modifiable risk factors for cognitive decline 
that have been highlighted in previous reviews
There is some evidence from studies looking at risk factors 
for cognitive decline that diet, physical activity, smoking and 
depression may affect the rate of cognitive decline. A Medi-
terranean diet has been associated with lower risks of devel-
oping cognitive disorders and reduced rate of progression 
to dementia in recent meta-analyses [37, 38]. There is low 
quality evidence from observational studies in the general 
population that the risk of dementia is lowered by omega-3 
fatty acids and vegetable intake [39]. In a recent review, an 
increase in leisure-time physical activity was associated with 
a 10% reduction in dementia risk [40]. In people with T2D, 
there is evidence that suggests physical activity may not 
affect the risk of cognitive decline [41], but a low intake of 
saturated and trans-fat, and a high intake of polyunsaturated 
fat since midlife has been associated with reduced cognitive 
decline [42]. In the general population, heavy smoking in 
mid-life more than doubles the risk of developing dementia 
and people actively smoking in later life have a higher risk 
of incident dementia [43, 44].
Depression is another potentially important factor, with 
depression affecting up to 39% of people living with T2D 
[45] and people with T2D and depression being twice as 
likely to develop dementia [46, 47].
This review will update and synthesise the most recent 
evidence from longitudinal observation studies describing 
modifiable risk factors that predict the progression of MCI 
to dementia in people living with T2D, prediabetes or MetS.
Methods
We used searched for the relevant literature in Medine, 
Embase, PsycINFO, PsycArticles and Web of Science from 
inception through to 20.3.18. No limits were set for language 
or date of publication. References of included articles and 
relevant reviewed were also searched. The search strategy 
can be found in ESM Appendix 1.
We included longitudinal studies involving people living 
with T2D, prediabetes or MetS diagnosed with MCI. MCI 
was defined as cognitive impairment identified from objec-
tive neuropsychological tests, in the absence of dementia 
or significant functional impairment. Studies recruited from 
either the general population, or from clinical settings where 
MCI had already been diagnosed. Modifiable risk factors 
were risks that could be influenced by changes in lifestyle 
or medical treatment.
The exclusion criteria for studies were: (1) cross-sectional 
studies, (2) studies not reporting the outcome measures of 
interest, (3) proceedings from conferences not published in 
peer-reviewed journals, and (4) studies on patients with dia-
betes where the mean age of participants was < 60 if type of 
diabetes not specified.
Data extraction and quality assessment
Two authors (KP, NM) independently extracted study char-
acteristics and findings into specific data extraction tables. 
Any disagreements were resolved by discussion with a third 
author (CC). The risk of bias was independently evaluated 
by the same authors by comparison against criteria based 
on previously published checklists [4, 16]. Studies were 
given a quality score out of 10 based on criteria listed in 
ESM Appendix 2 with higher scores indicating higher qual-
ity. Studies were rated 0–2 across five domains: population 
selection and recruitment, participation at follow-up, dia-
betes and MetS assessment, dementia assessment and data 
analysis.
Analysis
Analysis started with a narrative synthesis of the data. Het-
erogeneity of methods, outcomes and populations were 
assessed to determine the appropriateness of subsequent 
meta-analysis. Where the data allowed, the results from three 
or more studies were pooled using a random-effects model 
and pooled odds ratios for binary outcomes (progression to 
dementia/no progression). The meta-analysis was done using 
RevMan 5.3 from the Cochrane Collaboration. Where meta-
analysis was not possible, the findings have been described 
narratively.
Results
Overview of included studies
The results of our search strategy have been summarised in 
a PRISMA flow diagram in Fig. 1. Details of the included 
studies can be found in Table 1 and this has been summa-
rised below. We included 15 articles reporting 12 studies 
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with 6865 participants [48–59]. Eight studies only included 
people with diabetes or MetS, while data for patients with 
diabetes were extracted from reports of four studies. Half 
of the studies were community-based and half were clini-
cal studies. Eight studies included people with diabetes, 
three studies featured participants with MetS and one study 
reported outcomes for both diabetes and MetS. Three stud-
ies took place in Italy, two in China, two in Singapore and 
the remainder in France, the Netherlands, Sweden, the UK 
and the USA. Three studies looked at the risk of progres-
sion of MCI to AD, while nine studies looked at progression 
to all cause dementia. There was moderate heterogeneity 
in the studies included in the main meta-analysis with an 
overall I2 statistic of 52%. A funnel plot of the studies has 
been included in ESM Appendix 3. The plot appears mostly 
symmetrical; however, there is some asymmetry near the 
base suggesting the absence of lower powered studies with 
negative results which may raise the possibility of publica-
tion bias.
Quality of included studies
Most of the studies were of moderate to high quality based 
on the criteria described above (scoring 5 or higher). The 
study quality scores are summarised in Table 1. No single 
criterion was judged to be essential and no studies were 
excluded based on scores. Lower scoring study reports 
contained little detail regarding the population sample or 
response rates for inclusion in the study, and the diagnosis 
of diabetes was based on medical records rather than direct 
measurement.
Impact of metabolic status on risk of progression of MCI 
to dementia
Figure 2 shows the overall the unadjusted pooled odds ratio 
for the progression of MCI to dementia in people with dia-
betes or MetS from 12 studies was 1.67 (95% CI 1.27–2.19). 
The risk was similar in studies that recruited from memory 
clinics (pooled OR from six studies 1.84, 95% CI 1.27–2.67) 
compared to epidemiological studies [pooled OR from six 
studies 1.60, (95% CI 1.11–2.30)]. Figure 3 shows that the 
pooled odds ratio for progression in people with diabetes 
was 1.53 (95% CI 1.20–1.97) while the pooled odds ratio 
in people with MetS was 2.95 (95% CI 1.23–7.05). Two 
studies that separated the risks of diabetes and prediabetes/
MetS also found a trend towards a higher risk for people 
with prediabetes and MetS [48, 55]. The adjusted HR for 
all cause dementia in one of the studies was 4.96 (95% CI 
2.27–10.84) in people with prediabetes, nearly double the 
HR of 2.87 (95% CI 1.30–6.34) in people with T2D; simi-
larly the adjusted HR for MetS in the other study was 4.25 
(95% CI 1.29–14.00), while the adjusted HR for people with 
diabetes was 2.47 (95% CI 1.92–4.19).
Type of dementia
Four studies provided a breakdown of the type of dementia 
diagnosed when participants progressed from MCI [48, 50, 
53, 59]. Data from all four studies were from people with 
diabetes. In three out of the four studies, the most common 
diagnosis was AD with the proportion of people diagnosed 
with AD varying between 23 and 84%. One study reported 
VaD to be the most common diagnosis (46%) while the 
range of diagnosis of VaD in other studies was between 4 
and 14%. Mixed dementia was diagnosed in 4–11% of par-
ticipants and Lewy body dementia was diagnosed in 1–7% 
of participants.
Fig. 1  PRISMA flow diagram of study
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Fig. 2  Meta-analysis of pooled odds ratios of risk of progression from MCI to dementia in people with diabetes, prediabetes or metabolic syn-
drome
Fig. 3  Subgroup analysis comparing pooled odds ratios of risk of progression from MCI to dementia in people with diabetes and metabolic syn-
drome
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Time to diagnosis
Three studies reported times to diagnosis of dementia in 
people living with diabetes who had MCI [48, 50, 53]. 
The time to diagnosis was shorter for people with diabe-
tes compared to people without in all three studies, with a 
median time to diagnosis of 1.83–1.97 years, accelerated by 
4 months–3 years.
Risk factors for progression of MCI to dementia 
in people with diabetes and MetS
Cardiovascular and metabolic risks
Hypertension In one study, the risk of incident dementia 
appeared to be nearly doubled in the presence of hyperten-
sion but this did not reach statistical significance (adjusted 
HR 1.84 with 95% CI 0.55–6.22). In the other study, the rate 
of incident dementia per 1000 person-years was four times 
higher in people with MetS who had hypertension when 
compared to people without: 72.21 (95% CI 36.11–144.39) 
for hypertension and MetS compared to 17.49 (95% CI 
4.37–69.92) for people with hypertension without MetS.
Central obesity Similar to the results above, the adjusted 
HR for central obesity was nearly three times higher, with-
out reaching statistical significance (adjusted HR 2.97 with 
a 95% CI of 0.85–10.40) with an incident dementia rate of 
80.93 per 1000 person-years (95% CI 42.11–155.54).
Dyslipidaemia Like the previous two results, the adjusted 
HR for dyslipidaemia also did not reach statistical signifi-
cance (2.04 with a 95% CI 0.61–6.78)—however, there 
seemed to be a marked difference between incident dementia 
rates associated with high triglycerides compared with low 
HDL. The rate of incident dementia per 1000 patient-years 
in MetS was calculated to be 84.53 (95% CI 37.98–188.16) 
with high triglycerides compared to 42.96 (16.12–114.46) 
for low HDL cholesterol.
Multiple cardiovascular risk factors Both the above stud-
ies looked at people with MetS and therefore looked at the 
impact of having three or more risk factors out of hyperten-
sion, central obesity, dyslipidaemia and hyperglycaemia. 
People with three or more risk factors were nearly five times 
more likely to progress from MCI to dementia (adjusted HR 
4.92 95% CI 1.39–17.40). The incident rate of progression 
to dementia with three or more risks factors was 67.6 (95% 
CI 35.17–129.93).
Statin use One of the other included studies explored the 
impact of statins on the risk of progressing from MCI to 
dementia in people with diabetes [53]. The use of a sta-
tin was associated with a lower risk of progression with an 
adjusted HR of 0.86 (95% CI 0.84–0.90).
Glycaemic control Two studies on people with diabetes 
looked at the impact of aspects of glycaemic control on the 
risks of MCI progressing to dementia [50, 53]. A longer 
duration of diabetes was associated with an increasing risk 
of developing dementia. The adjusted HRs increased from 
1.04 (95% CI 09.98–1.10) after 2 years of living with dia-
betes to 1.42 (95% CI 1.35–1.49) after more than 5 years. 
An HbA1c of 7% or more was associated with an increased 
risk of dementia with a HR of 1.30 (95% CI 1.11–1.57). 
Using insulin did not affect the risk of dementia, but oral 
hypoglycaemic agents appeared to reduce the risk of devel-
oping dementia (HR 0.93, 95% CI 0.90–0.96). Patients with 
diabetes who converted from MCI to dementia were more 
likely to have diabetic retinopathy and had reported more 
episodes of severe hypoglycaemia.
In patients with MetS, high blood glucose levels were 
associated with an incident rate of dementia of 14.63 (95% 
CI 2.06–103.88) per 1000 person-years—the lowest calcu-
lated incident rate of the five features or MetS [58].
Other risk factors for the progression of MCI 
to dementia in people with diabetes, prediabetes 
and MetS
None of the studies in this review reported data on the 
impact of diet, physical activity or depression in the progres-
sion of MCI to dementia in people with T2D, prediabetes 
or MetS. There was some evidence on non-modifiable risks 
which we will only briefly summarise as this was not the 
focus of this review. One study reported age as a major risk 
factor with the risk of progression to dementia increasing 
dramatically with age and people with diabetes and MCI 
aged 75–85 had twice the dementia risk of people aged 
65–75 [53]. There was no evidence of significant risks from 
other lifestyle or demographic factors. Two studies reported 
no significant increase in the risk of converting to dementia 
in people with diabetes from gender, education level, smok-
ing, heavy drinking or previous cerebrovascular disease [50, 
53]. The APOEε4 allele was found to be associated with 
an increase in the risk of progressing to dementia in two 
studies [50, 54], but not in one study in a younger Chinese 
population [53].
Discussion
We have synthesised evidence on diabetes, prediabetes and 
MetS and other cardiovascular risk factors with regards to 
risk of progressing from MCI to dementia. We used a thor-
ough and inclusive search strategy with no limitations on 
language or date of publication. Our results are likely to 
represent the most up to date and comprehensive overview 
of this topic.
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Summary of results
Diabetes, prediabetes and MetS were all associated with 
increased risks of progression of MCI to dementia. The 
pooled odds ratio for progression in people with diabetes 
was 1.53 (95% CI 1.20–1.97) while the pooled odds ratio in 
people with MetS was 2.95 (95% CI 1.23–7.05). In people 
with T2D, a longer duration of diabetes and the presence 
of retinopathy were associated with an increased risk of 
progression from MCI to dementia, while statins and oral 
hypoglycaemic agents appeared to reduce the risk. For peo-
ple with MetS, the presence of multiple cardiovascular risk 
factors was a significant risk factor for progression from 
MCI to dementia. The highest rates of incident dementia 
were associated with raised triglycerides, abdominal obesity 
and hypertension, with lower rates associated with low HDL 
cholesterol and raised blood glucose levels. Overall, most of 
the studies included in this review tended towards a higher 
risk of progression to dementia in people with diabetes or 
MetS. Two studies reported results that tended towards a 
lower risk of progression of MCI to dementia in people with 
diabetes, and one of those was rated high quality [52, 57]. 
The higher quality study looked at rates of Alzheimer’s dis-
ease in a Chinese population [52]. Based on the results from 
other studies in a similar population, this study may have 
only detected half of all cause dementia (particularly miss-
ing cases of VaD), and therefore the risk of progression to 
dementia may have appeared significantly lower than other 
studies.
Comparison to previous literature
There was conflicting evidence in this review on the role of 
APOEe4 in the progression of MCI to dementia with one 
study reporting no evidence of links between APOEe4 and 
progression to dementia [53]. This study involved a com-
munity Chinese population and it was also the only study 
that showed a higher risk of progression to VaD than Alz-
heimer’s disease. Therefore, the pathways for progression 
of MCI to dementia might be different in different ethnic 
groups and the type of dementia developed may vary.
There was no clear evidence for the impact of individual 
cardiovascular risk factors on the rate of progression of MCI 
to dementia. This is similar to findings in the general popu-
lation where individual risk factors such as hypertension or 
hypercholesterolaemia have not been shown to increase the 
rate of progression of MCI to dementia [4]. However, when 
three or more risk factors clustered together as MetS, the 
risks increased substantially. This may represent a cumula-
tive effect or be due to other pathology associated with MetS 
that might include chronic inflammation, insulin-resistance 
and the endocrine influence of adipose tissue [23].
The pooled OR for progression of MCI to dementia in 
people with MetS tended towards being higher than people 
with diabetes. This might be due to more active treatment 
of risk factors such as hypertension and raised cholesterol 
in patients with diabetes. Renin–angiotensin system drugs 
are very commonly used in diabetes for treating hyperten-
sion and micro-albuminuria, and these medicines have been 
shown to be protective against cognitive impairment [30].
With regards to dyslipidaemias, previous studies have 
focused on hypercholesterolaemia with no evidence that 
raised cholesterol in later life affects dementia risk [4, 60]. 
However, statins have previously been shown to substantially 
lower the risk of dementia [61]—this effect was endorsed 
by another study included in this review [53] and patients 
with T2D are likely to be on statins because of their raised 
cardiovascular risk and lower target cholesterol levels. The 
particular dyslipidaemia associated with MetS may also 
point to a more significant role for raised triglycerides in 
the aetiology of dementia in this group.
Oral hypoglycaemic drugs (but not insulin) were also 
found to have beneficial effects in this review, so the com-
bination of multiple treatments for multiple risk factors in 
people with T2D may explain why the risks in this group 
are comparatively lower than prediabetes or MetS. Pursuing 
a similar pro-active treatment of risk factors in prediabetes 
or MetS could help with a 10–25% reduction in risk factors 
that could prevent more than a million cases of dementia 
worldwide [29].
Implications for practice
The results of this review have identified a number of poten-
tial risk factors that could be targeted to reduce or slow down 
the progression of MCI to dementia in people with the MetS 
or diabetes. Optimising the treatment of cardiovascular risk 
factors in people with MetS may be a potentially important 
therapeutic opportunity. Promoting the use of statins and 
oral hypoglycaemic agents in patients with T2D and MCI 
may also be important, and needs to be weighed against the 
recent trend towards relaxing HbA1c targets in older people 
with T2D. Tight control of blood glucose levels with an 
HbA1c ≤ 48 mmol/mol (7%) could potentially have a mean-
ingful impact by delaying progress to dementia that could 
happen within 2 years of a diagnosis of MCI.
Limitations of research
There may have been risk factors that were analysed in stud-
ies but not reported so we may have under-reported null 
results not described in the published articles. Most of the 
risk factors for progression were described in studies on 
patients with MetS and there was a lack of studies looking 
at risk factors for progression in patients with T2D. From 
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the study reports it was also difficult to distinguish between 
treated and untreated risk factors. Diagnosing dementia 
and the types of dementia can be challenging and may have 
affected the accuracy of the findings. The process of meas-
uring the conversion of MCI to dementia has limitations as 
the only difference between MCI and mild dementia may be 
the interpretation of the impact of the condition on activities 
of daily living and may be at risk of bias [62]. Addition-
ally, diabetes itself could impact on a person’s function over 
time and contribute to frailty which makes attribution of 
MCI progression to risk factors even more difficult. Only 
4 out of 12 studies provided details of the type of dementia 
diagnosed.
Suggestions for future research
There are a number of questions regarding the development 
of cognitive disorders in diabetes, prediabetes and MetS 
raised by this review. More research is needed on the role of 
APOEe4 in different ethnicities and whether this impacts the 
type of dementia that develops from MCI. Most of the stud-
ies included in this review did not distinguish between aMCI 
and non-aMCI, and given the significant variation in rates 
of progression to Alzheimer’s disease across the studies, it 
would be useful to know if this was reflected in the preced-
ing MCI stage. The role of raised triglycerides in developing 
dementia is potentially under-researched and may be impor-
tant in people with MetS. We did not find any studies that 
looked at the impact of identifying or treating depression in 
patients with MCI and diabetes, prediabetes or MetS.
Developing and evaluating multi-modal interventions to 
harness lifestyle and therapeutic strategies to target modi-
fiable risk factors and reduce the progression of MCI to 
dementia in these high risk groups may have the potential for 
significant patient benefit. However, a key question for such 
interventions would be the optimal timing for delivery—
whether treatment can be effective after the development 
or MCI, or whether interventions are needed in mid-life. It 
would also be helpful for studies to report more details about 
outcome measures regarding conversion of MCI to demen-
tia. Quantifiable changes in cognition and more details about 
subsequent dementia diagnoses would help distinguish 
between progression of cognitive impairment and worsen-
ing frailty which would support better understanding of the 
nature of progression and provide more robust outcomes less 
reliant on subjective interpretation.
Conclusion
Diabetes, prediabetes and MetS were all associated with 
increased risks of progression of MCI to dementia. The 
pooled odds ratio for progression in people with diabetes 
was 1.53 (95% CI 1.20–1.97) while the pooled odds ratio in 
people with MetS was 2.95 (95% CI 1.23–7.05). In people 
with T2D, a longer duration of diabetes and the presence 
of retinopathy were associated with an increased risk of 
progression from MCI to dementia, while statins and oral 
hypoglycaemic agents appeared to reduce the risk. For peo-
ple with MetS, the presence of multiple cardiovascular risk 
factors was a significant risk factor for progression from 
MCI to dementia. Intensive cardiovascular risk reduction 
and lifestyle changes for patients presenting with MCI and 
diabetes, prediabetes or MetS may be important in reducing 
the incidence of dementia in this high risk population.
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